Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01777152 · ClinicalTrials.gov registry record · Phase 3
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas
A Phase 3 study, sponsored by Seagen.
- Completed
- Registry status
- Phase 3
- Development phase
- 452
- Enrollment target
NCT01777152 is a Phase 3 study that has completed, run by Seagen. The registered enrollment target is 452 participants.
The verdict
NCT01777152, a Phase 3 study, has completed, sponsored by Seagen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 452 participants
- Enrollment target
Study Summary
This is a double-blind, randomized, multicenter, phase 3 clinical trial to compare the efficacy and safety of brentuximab vedotin in combination with CHP with the standard-of-care CHOP in patients with CD30-positive mature T-cell lymphomas.
Interventions
- DRUG prednisone
- DRUG cyclophosphamide
- DRUG doxorubicin
- DRUG brentuximab vedotin
- DRUG vincristine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 452 participants |
| Start Date | 2013-01-31 |
| Est. Completion | 2020-10-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01777152
The ClinicalTrials.gov registry entry for NCT01777152 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 452 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which prednisone is the first listed.
NCT01777152 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01777152 about?
NCT01777152 is a clinical study titled "ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas". This is a double-blind, randomized, multicenter, phase 3 clinical trial to compare the efficacy and safety of brentuximab vedotin in combination with CHP with the standard-of-care CHOP in patients with CD30-positive mature T-cell lymphomas.
What is the current status of trial NCT01777152?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 452 participants. The study started on 2013-01-31. Estimated completion is 2020-10-02.
What interventions are being tested in trial NCT01777152?
The interventions under investigation include: prednisone (DRUG), cyclophosphamide (DRUG), doxorubicin (DRUG), brentuximab vedotin (DRUG), vincristine (DRUG).
Who is sponsoring clinical trial NCT01777152?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.